process for the production of 9,10 - dihydroergosin and its physiologically vertraeglichen saeureadditionssalzen

摘要

(I) and its acid addn. salts are prepd. by hydrogenation of ergosine in dimethylformamide with shaking, at normal press., in the dark using a 10% Pd/C catalyst and opt. converting (I) to its salts. (I) is used to treat arterial hypertension, peripheral angiopathy, cerebral circulatory troubles, cardiac arrythmia and migraine. It is administered parenterally or enterally in daily doses of 0.3-10 7g/70 kg Acute toxicity (methanesulphonate i.p. in mice LD50=72.2 mg/kg, i.p. in rats=N400mg/kg) and pharmacological tests (arterial press., effect on heart, antiadrenaline effect, antiserotonin effect) are described. The reaction is effected rapidly reducing by-prods. due to degradation and giving high yields of (I).